

Global CAR-T Therapy in Haematological Malignancy Market Insight and Forecast to 2026

<https://marketpublishers.com/r/GE515346A122EN.html>

Date: August 2020

Pages: 129

Price: US\$ 2,350.00 (Single User License)

ID: GE515346A122EN

Abstracts

The research team projects that the CAR-T Therapy in Haematological Malignancy market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2026.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Celgene (Juno Therapeutics)

Sorrento Therapeutics

Pfizer

Novartis

Aurora BioPharma

Gilead (Kite Pharma)

Bluebird Bio

Autolus Therapeutics

CARsgen Therapeutics

Mustang Bio

Collectis

Allogene Therapeutics

Celyad

By Type

Allogeneic

Autologous

By Application

Hospitals

Cancer Research Centers

Others

By Regions/Countries:

North America

United States

Canada

Mexico

East Asia

China

Japan

South Korea

Europe

Germany

United Kingdom

France

Italy

South Asia

India

Southeast Asia

Indonesia

Thailand

Singapore

Middle East

Turkey

Saudi Arabia

Iran

Africa

Nigeria

South Africa

Oceania

Australia

South America

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective

organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of CAR-T Therapy in Haematological Malignancy 2015-2020, and development forecast 2021-2026 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2019.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2015-2020 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2021-2026. Further the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers majority Product Types in the CAR-T Therapy in Haematological Malignancy Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis by Application Type: Based on the CAR-T Therapy in Haematological Malignancy Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.

Market Trends: Market key trends which include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report will provide with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with

the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the CAR-T Therapy in Haematological Malignancy market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by CAR-T Therapy in Haematological Malignancy Revenue

1.4 Market Analysis by Type

1.4.1 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Allogeneic

1.4.3 Autologous

1.5 Market by Application

1.5.1 Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2021-2026

1.5.2 Hospitals

1.5.3 Cancer Research Centers

1.5.4 Others

1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth

1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections

1.6.2 Covid-19 Impact: Commodity Prices Indices

1.6.3 Covid-19 Impact: Global Major Government Policy

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global CAR-T Therapy in Haematological Malignancy Market Perspective (2021-2026)

2.2 CAR-T Therapy in Haematological Malignancy Growth Trends by Regions

2.2.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions: 2015 VS 2021 VS 2026

2.2.2 CAR-T Therapy in Haematological Malignancy Historic Market Size by Regions (2015-2020)

2.2.3 CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Regions (2021-2026)

3 MARKET COMPETITION BY MANUFACTURERS

3.1 Global CAR-T Therapy in Haematological Malignancy Production Capacity Market Share by Manufacturers (2015-2020)

3.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Manufacturers (2015-2020)

3.3 Global CAR-T Therapy in Haematological Malignancy Average Price by Manufacturers (2015-2020)

4 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY PRODUCTION BY REGIONS

4.1 North America

4.1.1 North America CAR-T Therapy in Haematological Malignancy Market Size (2015-2026)

4.1.2 CAR-T Therapy in Haematological Malignancy Key Players in North America (2015-2020)

4.1.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

4.1.4 North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

4.2 East Asia

4.2.1 East Asia CAR-T Therapy in Haematological Malignancy Market Size (2015-2026)

4.2.2 CAR-T Therapy in Haematological Malignancy Key Players in East Asia (2015-2020)

4.2.3 East Asia CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

4.2.4 East Asia CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

4.3 Europe

4.3.1 Europe CAR-T Therapy in Haematological Malignancy Market Size (2015-2026)

4.3.2 CAR-T Therapy in Haematological Malignancy Key Players in Europe (2015-2020)

4.3.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

4.3.4 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

4.4 South Asia

4.4.1 South Asia CAR-T Therapy in Haematological Malignancy Market Size (2015-2026)

4.4.2 CAR-T Therapy in Haematological Malignancy Key Players in South Asia (2015-2020)

4.4.3 South Asia CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

4.4.4 South Asia CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

4.5 Southeast Asia

4.5.1 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size (2015-2026)

4.5.2 CAR-T Therapy in Haematological Malignancy Key Players in Southeast Asia (2015-2020)

4.5.3 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

4.5.4 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

4.6 Middle East

4.6.1 Middle East CAR-T Therapy in Haematological Malignancy Market Size (2015-2026)

4.6.2 CAR-T Therapy in Haematological Malignancy Key Players in Middle East (2015-2020)

4.6.3 Middle East CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

4.6.4 Middle East CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

4.7 Africa

4.7.1 Africa CAR-T Therapy in Haematological Malignancy Market Size (2015-2026)

4.7.2 CAR-T Therapy in Haematological Malignancy Key Players in Africa (2015-2020)

4.7.3 Africa CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

4.7.4 Africa CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

4.8 Oceania

4.8.1 Oceania CAR-T Therapy in Haematological Malignancy Market Size (2015-2026)

4.8.2 CAR-T Therapy in Haematological Malignancy Key Players in Oceania (2015-2020)

4.8.3 Oceania CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

4.8.4 Oceania CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

4.9 South America

4.9.1 South America CAR-T Therapy in Haematological Malignancy Market Size (2015-2026)

4.9.2 CAR-T Therapy in Haematological Malignancy Key Players in South America (2015-2020)

4.9.3 South America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

4.9.4 South America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

4.10 Rest of the World

4.10.1 Rest of the World CAR-T Therapy in Haematological Malignancy Market Size (2015-2026)

4.10.2 CAR-T Therapy in Haematological Malignancy Key Players in Rest of the World (2015-2020)

4.10.3 Rest of the World CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)

4.10.4 Rest of the World CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

5 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY CONSUMPTION BY REGION

5.1 North America

5.1.1 North America CAR-T Therapy in Haematological Malignancy Consumption by Countries

5.1.2 United States

5.1.3 Canada

5.1.4 Mexico

5.2 East Asia

5.2.1 East Asia CAR-T Therapy in Haematological Malignancy Consumption by Countries

5.2.2 China

5.2.3 Japan

5.2.4 South Korea

5.3 Europe

5.3.1 Europe CAR-T Therapy in Haematological Malignancy Consumption by Countries

5.3.2 Germany

5.3.3 United Kingdom

5.3.4 France

5.3.5 Italy

5.3.6 Russia

5.3.7 Spain

5.3.8 Netherlands

5.3.9 Switzerland

5.3.10 Poland

5.4 South Asia

5.4.1 South Asia CAR-T Therapy in Haematological Malignancy Consumption by Countries

5.4.2 India

5.4.3 Pakistan

5.4.4 Bangladesh

5.5 Southeast Asia

5.5.1 Southeast Asia CAR-T Therapy in Haematological Malignancy Consumption by Countries

5.5.2 Indonesia

5.5.3 Thailand

5.5.4 Singapore

5.5.5 Malaysia

5.5.6 Philippines

5.5.7 Vietnam

5.5.8 Myanmar

5.6 Middle East

5.6.1 Middle East CAR-T Therapy in Haematological Malignancy Consumption by Countries

5.6.2 Turkey

5.6.3 Saudi Arabia

5.6.4 Iran

5.6.5 United Arab Emirates

5.6.6 Israel

5.6.7 Iraq

5.6.8 Qatar

5.6.9 Kuwait

5.6.10 Oman

5.7 Africa

5.7.1 Africa CAR-T Therapy in Haematological Malignancy Consumption by Countries

5.7.2 Nigeria

5.7.3 South Africa

5.7.4 Egypt

5.7.5 Algeria

5.7.6 Morocco

5.8 Oceania

5.8.1 Oceania CAR-T Therapy in Haematological Malignancy Consumption by Countries

5.8.2 Australia

5.8.3 New Zealand

5.9 South America

5.9.1 South America CAR-T Therapy in Haematological Malignancy Consumption by Countries

5.9.2 Brazil

5.9.3 Argentina

5.9.4 Columbia

5.9.5 Chile

5.9.6 Venezuela

5.9.7 Peru

5.9.8 Puerto Rico

5.9.9 Ecuador

5.10 Rest of the World

5.10.1 Rest of the World CAR-T Therapy in Haematological Malignancy Consumption by Countries

5.10.2 Kazakhstan

6 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY SALES MARKET BY TYPE (2015-2026)

6.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Type (2015-2020)

6.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2021-2026)

7 CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY CONSUMPTION MARKET BY APPLICATION(2015-2026)

7.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Application (2015-2020)

7.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2021-2026)

8 COMPANY PROFILES AND KEY FIGURES IN CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY BUSINESS

8.1 Celgene (Juno Therapeutics)

8.1.1 Celgene (Juno Therapeutics) Company Profile

8.1.2 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Specification

8.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.2 Sorrento Therapeutics

8.2.1 Sorrento Therapeutics Company Profile

8.2.2 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Specification

8.2.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.3 Pfizer

8.3.1 Pfizer Company Profile

8.3.2 Pfizer CAR-T Therapy in Haematological Malignancy Product Specification

8.3.3 Pfizer CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.4 Novartis

8.4.1 Novartis Company Profile

8.4.2 Novartis CAR-T Therapy in Haematological Malignancy Product Specification

8.4.3 Novartis CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.5 Aurora BioPharma

8.5.1 Aurora BioPharma Company Profile

8.5.2 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Specification

8.5.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.6 Gilead (Kite Pharma)

8.6.1 Gilead (Kite Pharma) Company Profile

8.6.2 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Specification

8.6.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Production

Capacity, Revenue, Price and Gross Margin (2015-2020)

8.7 Bluebird Bio

8.7.1 Bluebird Bio Company Profile

8.7.2 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Specification

8.7.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.8 Autolus Therapeutics

8.8.1 Autolus Therapeutics Company Profile

8.8.2 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Specification

8.8.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.9 CARsgen Therapeutics

8.9.1 CARsgen Therapeutics Company Profile

8.9.2 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Specification

8.9.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.10 Mustang Bio

8.10.1 Mustang Bio Company Profile

8.10.2 Mustang Bio CAR-T Therapy in Haematological Malignancy Product Specification

8.10.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.11 Collectis

8.11.1 Collectis Company Profile

8.11.2 Collectis CAR-T Therapy in Haematological Malignancy Product Specification

8.11.3 Collectis CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.12 Allogene Therapeutics

8.12.1 Allogene Therapeutics Company Profile

8.12.2 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Specification

8.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.13 Celyad

8.13.1 Celyad Company Profile

8.13.2 Celyad CAR-T Therapy in Haematological Malignancy Product Specification

8.13.3 Celyad CAR-T Therapy in Haematological Malignancy Production Capacity,

Revenue, Price and Gross Margin (2015-2020)

9 PRODUCTION AND SUPPLY FORECAST

9.1 Global Forecasted Production of CAR-T Therapy in Haematological Malignancy (2021-2026)

9.2 Global Forecasted Revenue of CAR-T Therapy in Haematological Malignancy (2021-2026)

9.3 Global Forecasted Price of CAR-T Therapy in Haematological Malignancy (2015-2026)

9.4 Global Forecasted Production of CAR-T Therapy in Haematological Malignancy by Region (2021-2026)

9.4.1 North America CAR-T Therapy in Haematological Malignancy Production, Revenue Forecast (2021-2026)

9.4.2 East Asia CAR-T Therapy in Haematological Malignancy Production, Revenue Forecast (2021-2026)

9.4.3 Europe CAR-T Therapy in Haematological Malignancy Production, Revenue Forecast (2021-2026)

9.4.4 South Asia CAR-T Therapy in Haematological Malignancy Production, Revenue Forecast (2021-2026)

9.4.5 Southeast Asia CAR-T Therapy in Haematological Malignancy Production, Revenue Forecast (2021-2026)

9.4.6 Middle East CAR-T Therapy in Haematological Malignancy Production, Revenue Forecast (2021-2026)

9.4.7 Africa CAR-T Therapy in Haematological Malignancy Production, Revenue Forecast (2021-2026)

9.4.8 Oceania CAR-T Therapy in Haematological Malignancy Production, Revenue Forecast (2021-2026)

9.4.9 South America CAR-T Therapy in Haematological Malignancy Production, Revenue Forecast (2021-2026)

9.4.10 Rest of the World CAR-T Therapy in Haematological Malignancy Production, Revenue Forecast (2021-2026)

9.5 Forecast by Type and by Application (2021-2026)

9.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)

9.5.2 Global Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Application (2021-2026)

10 CONSUMPTION AND DEMAND FORECAST

10.1 North America Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country

10.2 East Asia Market Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country

10.3 Europe Market Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country

10.4 South Asia Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country

10.5 Southeast Asia Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country

10.6 Middle East Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country

10.7 Africa Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country

10.8 Oceania Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country

10.9 South America Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country

10.10 Rest of the world Forecasted Consumption of CAR-T Therapy in Haematological Malignancy by Country

11 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS

11.1 Marketing Channel

11.2 CAR-T Therapy in Haematological Malignancy Distributors List

11.3 CAR-T Therapy in Haematological Malignancy Customers

12 INDUSTRY TRENDS AND GROWTH STRATEGY

12.1 Market Top Trends

12.2 Market Drivers

12.3 Market Challenges

12.4 Porter's Five Forces Analysis

12.5 CAR-T Therapy in Haematological Malignancy Market Growth Strategy

13 ANALYST'S VIEWPOINTS/CONCLUSIONS

14 APPENDIX

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.2 Data Source

14.2 Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Global CAR-T Therapy in Haematological Malignancy Market Share by Type: 2020 VS 2026

Table 2. Allogeneic Features

Table 3. Autologous Features

Table 11. Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2020 VS 2026

Table 12. Hospitals Case Studies

Table 13. Cancer Research Centers Case Studies

Table 14. Others Case Studies

Table 21. Commodity Prices-Metals Price Indices

Table 22. Commodity Prices- Precious Metal Price Indices

Table 23. Commodity Prices- Agricultural Raw Material Price Indices

Table 24. Commodity Prices- Food and Beverage Price Indices

Table 25. Commodity Prices- Fertilizer Price Indices

Table 26. Commodity Prices- Energy Price Indices

Table 27. G20+: Economic Policy Responses to COVID-19

Table 28. CAR-T Therapy in Haematological Malignancy Report Years Considered

Table 29. Global CAR-T Therapy in Haematological Malignancy Market Size YoY Growth 2021-2026 (US\$ Million)

Table 30. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions: 2021 VS 2026

Table 31. North America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2026) (US\$ Million)

Table 32. East Asia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2026) (US\$ Million)

Table 33. Europe CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2026) (US\$ Million)

Table 34. South Asia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2026) (US\$ Million)

Table 35. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2026) (US\$ Million)

Table 36. Middle East CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2026) (US\$ Million)

Table 37. Africa CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2026) (US\$ Million)

Table 38. Oceania CAR-T Therapy in Haematological Malignancy Market Size YoY

Growth (2015-2026) (US\$ Million)

Table 39. South America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2026) (US\$ Million)

Table 40. Rest of the World CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2026) (US\$ Million)

Table 41. North America CAR-T Therapy in Haematological Malignancy Consumption by Countries (2015-2020)

Table 42. East Asia CAR-T Therapy in Haematological Malignancy Consumption by Countries (2015-2020)

Table 43. Europe CAR-T Therapy in Haematological Malignancy Consumption by Region (2015-2020)

Table 44. South Asia CAR-T Therapy in Haematological Malignancy Consumption by Countries (2015-2020)

Table 45. Southeast Asia CAR-T Therapy in Haematological Malignancy Consumption by Countries (2015-2020)

Table 46. Middle East CAR-T Therapy in Haematological Malignancy Consumption by Countries (2015-2020)

Table 47. Africa CAR-T Therapy in Haematological Malignancy Consumption by Countries (2015-2020)

Table 48. Oceania CAR-T Therapy in Haematological Malignancy Consumption by Countries (2015-2020)

Table 49. South America CAR-T Therapy in Haematological Malignancy Consumption by Countries (2015-2020)

Table 50. Rest of the World CAR-T Therapy in Haematological Malignancy Consumption by Countries (2015-2020)

Table 51. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Specification

Table 52. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Specification

Table 53. Pfizer CAR-T Therapy in Haematological Malignancy Product Specification

Table 54. Novartis CAR-T Therapy in Haematological Malignancy Product Specification

Table 55. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Specification

Table 56. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Specification

Table 57. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Specification

Table 58. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Specification

Table 59. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Specification

Table 60. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Specification

Table 61. Collectis CAR-T Therapy in Haematological Malignancy Product Specification

Table 62. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Specification

Table 63. Celyad CAR-T Therapy in Haematological Malignancy Product Specification

Table 101. Global CAR-T Therapy in Haematological Malignancy Production Forecast by Region (2021-2026)

Table 102. Global CAR-T Therapy in Haematological Malignancy Sales Volume Forecast by Type (2021-2026)

Table 103. Global CAR-T Therapy in Haematological Malignancy Sales Volume Market Share Forecast by Type (2021-2026)

Table 104. Global CAR-T Therapy in Haematological Malignancy Sales Revenue Forecast by Type (2021-2026)

Table 105. Global CAR-T Therapy in Haematological Malignancy Sales Revenue Market Share Forecast by Type (2021-2026)

Table 106. Global CAR-T Therapy in Haematological Malignancy Sales Price Forecast by Type (2021-2026)

Table 107. Global CAR-T Therapy in Haematological Malignancy Consumption Volume Forecast by Application (2021-2026)

Table 108. Global CAR-T Therapy in Haematological Malignancy Consumption Value Forecast by Application (2021-2026)

Table 109. North America CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026 by Country

Table 110. East Asia CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026 by Country

Table 111. Europe CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026 by Country

Table 112. South Asia CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026 by Country

Table 113. Southeast Asia CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026 by Country

Table 114. Middle East CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026 by Country

Table 115. Africa CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026 by Country

Table 116. Oceania CAR-T Therapy in Haematological Malignancy Consumption

Forecast 2021-2026 by Country

Table 117. South America CAR-T Therapy in Haematological Malignancy Consumption

Forecast 2021-2026 by Country

Table 118. Rest of the world CAR-T Therapy in Haematological Malignancy

Consumption Forecast 2021-2026 by Country

Table 119. CAR-T Therapy in Haematological Malignancy Distributors List

Table 120. CAR-T Therapy in Haematological Malignancy Customers List

Table 121. Porter's Five Forces Analysis

Table 122. Key Executives Interviewed

Figure 1. North America CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 2. North America CAR-T Therapy in Haematological Malignancy Consumption Market Share by Countries in 2020

Figure 3. United States CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 4. Canada CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 5. Mexico CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 6. East Asia CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 7. East Asia CAR-T Therapy in Haematological Malignancy Consumption Market Share by Countries in 2020

Figure 8. China CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 9. Japan CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 10. South Korea CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 11. Europe CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate

Figure 12. Europe CAR-T Therapy in Haematological Malignancy Consumption Market Share by Region in 2020

Figure 13. Germany CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 14. United Kingdom CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 15. France CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 16. Italy CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 17. Russia CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 18. Spain CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 19. Netherlands CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 20. Switzerland CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 21. Poland CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 22. South Asia CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate

Figure 23. South Asia CAR-T Therapy in Haematological Malignancy Consumption Market Share by Countries in 2020

Figure 24. India CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 25. Pakistan CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 26. Bangladesh CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 27. Southeast Asia CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate

Figure 28. Southeast Asia CAR-T Therapy in Haematological Malignancy Consumption Market Share by Countries in 2020

Figure 29. Indonesia CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 30. Thailand CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 31. Singapore CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 32. Malaysia CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 33. Philippines CAR-T Therapy in Haematological Malignancy Consumption and

Growth Rate (2015-2020)

Figure 34. Vietnam CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 35. Myanmar CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 36. Middle East CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate

Figure 37. Middle East CAR-T Therapy in Haematological Malignancy Consumption Market Share by Countries in 2020

Figure 38. Turkey CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 39. Saudi Arabia CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 40. Iran CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 41. United Arab Emirates CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 42. Israel CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 43. Iraq CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 44. Qatar CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 45. Kuwait CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 46. Oman CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 47. Africa CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate

Figure 48. Africa CAR-T Therapy in Haematological Malignancy Consumption Market Share by Countries in 2020

Figure 49. Nigeria CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 50. South Africa CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 51. Egypt CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 52. Algeria CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 53. Morocco CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 54. Oceania CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate

Figure 55. Oceania CAR-T Therapy in Haematological Malignancy Consumption Market Share by Countries in 2020

Figure 56. Australia CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 57. New Zealand CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 58. South America CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate

Figure 59. South America CAR-T Therapy in Haematological Malignancy Consumption Market Share by Countries in 2020

Figure 60. Brazil CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 61. Argentina CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 62. Columbia CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 63. Chile CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 64. Venezuelal CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 65. Peru CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 66. Puerto Rico CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 67. Ecuador CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 68. Rest of the World CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate

Figure 69. Rest of the World CAR-T Therapy in Haematological Malignancy Consumption Market Share by Countries in 2020

Figure 70. Kazakhstan CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2015-2020)

Figure 71. Global CAR-T Therapy in Haematological Malignancy Production Capacity Growth Rate Forecast (2021-2026)

Figure 72. Global CAR-T Therapy in Haematological Malignancy Revenue Growth Rate

Forecast (2021-2026)

Figure 73. Global CAR-T Therapy in Haematological Malignancy Price and Trend Forecast (2015-2026)

Figure 74. North America CAR-T Therapy in Haematological Malignancy Production Growth Rate Forecast (2021-2026)

Figure 75. North America CAR-T Therapy in Haematological Malignancy Revenue Growth Rate Forecast (2021-2026)

Figure 76. East Asia CAR-T Therapy in Haematological Malignancy Production Growth Rate Forecast (2021-2026)

Figure 77. East Asia CAR-T Therapy in Haematological Malignancy Revenue Growth Rate Forecast (2021-2026)

Figure 78. Europe CAR-T Therapy in Haematological Malignancy Production Growth Rate Forecast (2021-2026)

Figure 79. Europe CAR-T Therapy in Haematological Malignancy Revenue Growth Rate Forecast (2021-2026)

Figure 80. South Asia CAR-T Therapy in Haematological Malignancy Production Growth Rate Forecast (2021-2026)

Figure 81. South Asia CAR-T Therapy in Haematological Malignancy Revenue Growth Rate Forecast (2021-2026)

Figure 82. Southeast Asia CAR-T Therapy in Haematological Malignancy Production Growth Rate Forecast (2021-2026)

Figure 83. Southeast Asia CAR-T Therapy in Haematological Malignancy Revenue Growth Rate Forecast (2021-2026)

Figure 84. Middle East CAR-T Therapy in Haematological Malignancy Production Growth Rate Forecast (2021-2026)

Figure 85. Middle East CAR-T Therapy in Haematological Malignancy Revenue Growth Rate Forecast (2021-2026)

Figure 86. Africa CAR-T Therapy in Haematological Malignancy Production Growth Rate Forecast (2021-2026)

Figure 87. Africa CAR-T Therapy in Haematological Malignancy Revenue Growth Rate Forecast (2021-2026)

Figure 88. Oceania CAR-T Therapy in Haematological Malignancy Production Growth Rate Forecast (2021-2026)

Figure 89. Oceania CAR-T Therapy in Haematological Malignancy Revenue Growth Rate Forecast (2021-2026)

Figure 90. South America CAR-T Therapy in Haematological Malignancy Production Growth Rate Forecast (2021-2026)

Figure 91. South America CAR-T Therapy in Haematological Malignancy Revenue Growth Rate Forecast (2021-2026)

Figure 92. Rest of the World CAR-T Therapy in Haematological Malignancy Production Growth Rate Forecast (2021-2026)

Figure 93. Rest of the World CAR-T Therapy in Haematological Malignancy Revenue Growth Rate Forecast (2021-2026)

Figure 94. North America CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026

Figure 95. East Asia CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026

Figure 96. Europe CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026

Figure 97. South Asia CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026

Figure 98. Southeast Asia CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026

Figure 99. Middle East CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026

Figure 100. Africa CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026

Figure 101. Oceania CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026

Figure 102. South America CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026

Figure 103. Rest of the world CAR-T Therapy in Haematological Malignancy Consumption Forecast 2021-2026

Figure 104. Channels of Distribution

Figure 105. Distributors Profiles

I would like to order

Product name: Global CAR-T Therapy in Haematological Malignancy Market Insight and Forecast to 2026

Product link: <https://marketpublishers.com/r/GE515346A122EN.html>

Price: US\$ 2,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE515346A122EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

